Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy
Phase 3
Completed
- Conditions
- Immunotherapy
- Registration Number
- NCT00540150
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Brief Summary
We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy.
Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.
- Detailed Description
see above
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
- informed consent of patient and/or parents
- age >6 and <18 years
- bronchial asthma I° or II°
- allergy on house dust-mite
Exclusion Criteria
- age <6 and >18 years
- vital capacity <80% or FEV1 <70%
- pregnancy
- inhalative or systemic steroid use
- bronchial asthma III° or IV°
- heavy exacerbation during the last 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety of the shortened specific immunotherapy. may 2004 - march 2005
- Secondary Outcome Measures
Name Time Method Exhaled nitric oxid (eNO) and immunogenicity (IgE, specific IgE, specific IgG) in both groups. may 2004 - march 2005
Trial Locations
- Locations (1)
Goethe University, Department of Pulmonology
🇩🇪Frankfurt, Hessen, Germany
Goethe University, Department of Pulmonology🇩🇪Frankfurt, Hessen, Germany